Biologic agents targeting inflammatory cytokines, comprising anti-immunoglobulin (Ig)E and anti-interleukin (IL)-4/IL-13, IL-5, IL-5R, and thymic stromal lymphopoietin (TSLP) have emerged as promising treatment options for patients with severe asthma (6). The gene discussed is IL13; the disease is asthma.